Jim Oates to Treatment Outcome
This is a "connection" page, showing publications Jim Oates has written about Treatment Outcome.
Connection Strength
0.117
-
Development of Biomarker Models to Predict Outcomes in Lupus Nephritis. Arthritis Rheumatol. 2016 08; 68(8):1955-63.
Score: 0.059
-
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 01; 74(1):112-123.
Score: 0.022
-
Peer approaches to self-management (PALS): comparing a peer mentoring approach for disease self-management in African American women with lupus with a social support control: study protocol for a randomized controlled trial. Trials. 2019 Aug 23; 20(1):529.
Score: 0.018
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.
Score: 0.009
-
Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008 Aug; 42(7):862-3.
Score: 0.009